Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
Sponsor: Hoffmann-La Roche
Summary
This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.
Official title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 Following Intrathecal Administration in Participants With Early Symptomatic Alzheimer's Disease
Key Details
Gender
All
Age Range
50 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-01-27
Completion Date
2030-03-05
Last Updated
2026-04-03
Healthy Volunteers
No
Conditions
Interventions
RO7812653
Participants will receive RO7812653 as per the schedule in the protocol
Placebo
Participants will receive placebo as per the schedule in the protocol
Locations (5)
Brain Research Center Amsterdam
Amsterdam, North Holland, Netherlands
Sahlgrenska Universitetssjukhuset
Mlndal, Sweden
Karolinska Universitetssjukhuset
Solna, Sweden
Southampton General Hospital
Southampton, Hampshire, United Kingdom
National Hospital For Neurology and Neurosurgery
London, United Kingdom